Cited by 1,124Diabetes Treatment and ManagementPeptidase Inhibition and AnalysisPancreatic function and diabetes

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T J, McIntosh, C H, Pederson, R A·1995·Endocrinology

Open this paper in CoChat — free account

Abstract

The combined actions of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide-1 (tGLP-1) may fully account for the incretin effect. These hormones are released from the small intestine in response to oral glucose and stimulate insulin release. Recently, evidence has been provided demonstrating the degradation of GIP-(1-42) and GLP-1-(7-36)NH2 by the serum enzyme dipeptidyl peptidase IV (DPP IV) into the biologically inactive products GIP-(3-42) and GLP-1-(9-36)NH2. The objective of the current investigation was to develop a method to monitor the degradation of these hormones in vivo. Synthetic peptides were radiolabeled and purified by HPLC. Subsequent degradation of the peptides under various conditions was then monitored by further HPLC analysis. Incubation of [125I]GIP-(1-42) or [125I]GLP-1-(7-36)NH2 with Wistar rat serum or purified DPP IV resulted in the major N-terminal-truncated products [125I]GIP-(3-42) and [125I]GLP-1-(9-36)NH2. These products were significantly reduced when the specific DPP IV inhibitor diprotin A was included in the incubation mixture and were absent when serum from DPP IV-deficient rats was used. When the labeled peptides were infused into rats at hormone levels within the physiological range, over 50% was metabolized to the truncated forms within 2 min. These products were absent when the tracers were infused into DPP IV-deficient animals. It is concluded that DPP IV may be a primary inactivating enzyme of both GIP and tGLP-1 in vivo. As the N-terminal-truncated products of the DPP IV cleavage may not be distinguished from the biologically active hormone by currently employed assays, reports of circulating hormone levels should be reconsidered. The method described in this manuscript may be useful for investigating the durations of action of GIP and tGLP-1 in normal and pathophysiological conditions.

Integrity signals

Registry

Crossref · 10.1210/endo.136.8.7628397

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
Holz, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 591
Proline-Dependent Structural and Biological Properties of Peptides and Proteins
Yaron, A., Naider, F. R., & Scharpé, S. (1993) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239309082572 · Cited by 551
A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-?-naphthylamide
Hopsu-Havu, V. K., & Glenner, G. G. (1966) · Histochemistry and Cell Biology · doi:10.1007/bf00577838 · Cited by 437
Entero-Insular Axis
Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371

Show all 36 references

Sorted by citations

Items 201–300 of 997

Do we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 114
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D’Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 107
Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1)
Wideman, R. D., Yu, I. L. Y., Webber, T. D., Verchere, C. B., Johnson, J. D., Cheung, A. T., & Kieffer, T. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600655103 · Cited by 106
Self-citation
Therapeutic potential for GIP receptor agonists and antagonists
Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 105
Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation
Kim, S., Nian, C., Doudet, D. J., & McIntosh, C. H. S. (2008) · Diabetes · doi:10.2337/db08-1101 · Cited by 106
Self-citation
Review article: a comparison of glucagon‐like peptides 1 and 2
Janssen, P., Rotondò, A., Mulè, F., & Tack, J. F. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12092 · Cited by 105
Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1
Hinke, S. A., Kühn‐Wache, K., Hoffmann, T., Pederson, R. A., McIntosh, C. H. S., & Demuth, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6607 · Cited by 103
Self-citation
A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence
Hildebrandt, M., Reutter, W. G., Arck, P., Rose, M., & Klapp, B. F. (2000) · Clinical Science · doi:10.1042/cs0990093 · Cited by 105
Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl- l -cis-4,5-methanoprolinenitrile-Based Inhibitors
Magnin, D. R., Robl, J. A., Sulsky, R. B., Augeri, D. J., Huang, Y., Simpkins, L. M., Taunk, P. C., Betebenner, D. A., Robertson, J. G., Abboa‐Offei, B. E., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049924d · Cited by 105
Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs – An Ab Initio Fragment Molecular Orbital Study
Arulmozhiraja, S., Matsuo, N., Ishitsubo, E., Okazaki, S., Shimano, H., & Tokiwa, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166275 · Cited by 103
Characterization of the Cellular and Metabolic Effects of a Novel Enzyme-Resistant Antagonist of Glucose-Dependent Insulinotropic Polypeptide
Gault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6364 · Cited by 103
The Isolated N-terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1
de Maturana, R. L., Willshaw, A., Kuntzsch, A., Rudolph, R., & Donnelly, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212147200 · Cited by 103
Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide
Pauly, R. P., Demuth, H., Rosche, F., Schmidt, J., White, H. A., Lynn, F. C., McIntosh, C. H. S., & Pederson, R. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90090-2 · Cited by 103
Self-citation
A VGF-Derived Peptide Attenuates Development of Type 2 Diabetes via Enhancement of Islet β-Cell Survival and Function
Stephens, S. B., Schisler, J. C., Hohmeier, H. E., An, J., Sun, A. Y., Pitt, G. S., & Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.011 · Cited by 102
Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans
Halim, M. A., Degerblad, M., Sundbom, M., Karlbom, U., Holst, J. J., Webb, D., & Hellström, P. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02006 · Cited by 107
Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system
D’Alessio, D. A., Lu, W. J., Sun, W. Y., Zheng, S., Yang, Q., Seeley, R. J., Woods, S. C., & Tso, P. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00911.2006 · Cited by 104
GLP‐1 (9–36) Amide, Cleavage Product of GLP‐1 (7–36) Amide, Is a Glucoregulatory Peptide
Elahi, D., Egan, J. M., Shannon, R. P., Meneilly, G. S., Khatri, A., Habener, J. F., & Andersen, D. K. (2008) · Obesity · doi:10.1038/oby.2008.229 · Cited by 104
A model for receptor–peptide binding at the glucagon‐like peptide‐1 (GLP‐1) receptor through the analysis of truncated ligands and receptors
Al‐Sabah, S., & Donnelly, D. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705453 · Cited by 100
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?
Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2003) · Neuropeptides · doi:10.1016/j.npep.2003.09.002 · Cited by 102
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity
Burcelin, R., & Gourdy, P. (2016) · Obesity Reviews · doi:10.1111/obr.12465 · Cited by 99
Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes
Hui, H., Zhao, X., & Perfetti, R. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.553 · Cited by 99
Oral delivery of bioencapsulated exendin‐4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta‐ TC 6 cells
Kwon, K., Nityanandam, R., New, J. S., & Daniell, H. (2012) · Plant Biotechnology Journal · doi:10.1111/pbi.12008 · Cited by 98
Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats
Xie, Z., Enkhjargal, B., Wu, L., Zhou, K., Sun, C., Hu, X., Gospodarev, V. V., Tang, J., You, C., & Zhang, J. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.040 · Cited by 97
Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion
Mizokami, A., Yasutake, Y., Higashi, S., Kawakubo‐Yasukochi, T., Chishaki, S., Takahashi, I., Takeuchi, H., & Hirata, M. (2014) · Bone · doi:10.1016/j.bone.2014.09.006 · Cited by 100
Glucagon-Like Peptide 21
Drucker, D. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7386 · Cited by 99
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits—the role of the GLP-1 receptor
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes
Gault, V. A., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01361-5 · Cited by 95
Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats
Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., Yoshikawa, S., Asano, O., & Tanaka, I. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4999 · Cited by 95
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Novikoff, A., O’Brien, S. L., Bernecker, M., Grandl, G., Kleinert, M., Knerr, P. J., Stemmer, K., Klingenspor, M., Zeigerer, A., DiMarchi, R. D., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101181 · Cited by 99
Exendin-4 decreases amphetamine-induced locomotor activity
Erreger, K., Davis, A. R., Poe, A. M., Greig, N. H., Stanwood, G. D., & Galli, A. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.014 · Cited by 96
The Corn Protein, Zein Hydrolysate, Administered into the Ileum Attenuates Hyperglycemia via Its Dual Action on Glucagon-Like Peptide-1 Secretion and Dipeptidyl Peptidase-IV Activity in Rats
Mochida, T., Hira, T., & Hara, H. (2010) · Endocrinology · doi:10.1210/en.2009-1510 · Cited by 95
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 103
K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease
Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 98
Self-citation
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes
Nielsen, L. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03460-4 · Cited by 93
GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and Humans
Gil‐Lozano, M., Pérez–Tilve, D., Álvarez-Crespo, M., Martís, A., Fernandez, A. M., Catalina, P. F., González-Matías, L. C., & Mallo, F. (2010) · Endocrinology · doi:10.1210/en.2009-0915 · Cited by 91
Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
Campbell, R. K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.015 · Cited by 92
Discovery and Structure−Activity Relationships of Piperidinone- and Piperidine-Constrained Phenethylamines as Novel, Potent, and Selective Dipeptidyl Peptidase IV Inhibitors
Pei, Z., Li, X., von Geldern, T. W., Longenecker, K. L., Pireh, D., Stewart, K. D., Backes, B. J., Lai, C., Lubben, T. H., Ballaron, S. J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061436d · Cited by 92
A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells
Lynn, F. C., Thompson, S. A., Pospisilik, J. A., Ehses, J. A., Hinke, S. A., Pamir, N., McIntosh, C. H. S., & Pederson, R. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0243fje · Cited by 91
Self-citation
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Attenuates Inflammation and Accelerates Epithelialization in Wounds of Diabetic ob/ob Mice
Schürmann, C., Linke, A., Engelmann-Pilger, K., Steinmetz, C., Mark, M., Pfeilschifter, J. M., Klein, T., & Frank, S. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191098 · Cited by 90
Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R–Dependent Glucose Homeostasis In Vivo
Baggio, L. L., Kim, J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s205 · Cited by 93
Hormonal Regulators of Appetite
Austin, J., & Marks, D. L. (2008) · International Journal of Pediatric Endocrinology · doi:10.1155/2009/141753 · Cited by 123
The Pharmacokinetics of Acyl, Desacyl and Total Ghrelin in Healthy Human Subjects
Tong, J., Dave, N., Mugundu, G., Davis, H., Gaylinn, B., Thorner, M., Tschöp, M., D'Alessio, D., & Desai, P. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0072 · Cited by 81
Obesity: pathophysiology and therapeutic interventions
Kong, Y., Yang, H., Nie, R., Zhang, X., Zuo, F., Zhang, H., & Nian, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00264-9 · Cited by 89
Perspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 96
Identification of angiotensin converting enzyme and dipeptidyl peptidase-IV inhibitory peptides derived from oilseed proteins using two integrated bioinformatic approaches
Han, R., Maycock, J., Murray, B. S., & Boesch, C. (2018) · Food Research International · doi:10.1016/j.foodres.2018.12.015 · Cited by 89
Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region
Dardevet, D. P., Mc, M., Neal, D. W., DiCostanzo, C. A., Snead, W., & Cherrington, A. D. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00035.2004 · Cited by 89
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 97
Development of Potent Glucagon-like Peptide-1 Agonists with High Enzyme Stability via Introduction of Multiple Lactam Bridges
Murage, E. N., Gao, G., Bisello, A., & Ahn, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100602m · Cited by 88
Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
Sinclair, E. M., & Drucker, D. J. (2005) · Physiology · doi:10.1152/physiol.00030.2005 · Cited by 93
The Anthocyanin Delphinidin 3-Rutinoside Stimulates Glucagon-Like Peptide-1 Secretion in Murine GLUTag Cell Line via the Ca2+/Calmodulin-Dependent Kinase II Pathway
Kato, M., Tani, T., Terahara, N., & Tsuda, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126157 · Cited by 88
Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice
Kim, S., Nian, C., Doudet, D. J., & McIntosh, C. H. S. (2008) · Diabetes · doi:10.2337/db07-1639 · Cited by 86
Self-citation
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 84
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Flatt, P. R. (2008) · Frontiers in bioscience · doi:10.2741/2956 · Cited by 85
Sitagliptin ameliorates thioacetamide-induced acute liver injury via modulating TLR4/NF-KB signaling pathway in mice
El‐Kashef, D. H., & Serrya, M. S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.019 · Cited by 84
Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP ‐ 1R activation
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D. L., & Furness, S. G. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 88
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Druce, M. R., MINNION, J. S., Field, B. C. T., Patel, S. R., Shillito, J. C., Tilby, M. J., Beale, K., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2008) · Endocrinology · doi:10.1210/en.2008-0828 · Cited by 84
Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide
Kuhre, R. E., Albrechtsen, N. J. W., Hartmann, B., Deacon, C. F., & Holst, J. J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.006 · Cited by 86
Extracellular Proteases as Targets for Drug Development
Čudić, M., & Fields, G. B. (2009) · Current Protein and Peptide Science · doi:10.2174/138920309788922207 · Cited by 84
Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model
Faivre, É., & Hölscher, C. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt174 · Cited by 84
Biological activity of GLP-1-analogues with N-terminal modifications
Siegel, E. G., Gallwitz, B., Scharf, G., Mentlein, R., Morys‐Wortmann, C., Fölsch, U. R., Schrezenmeir, J., Drescher, K., & Schmidt, W. E. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(98)00155-4 · Cited by 83
Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives
Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 87
Pharmacokinetics of Peptide–Fc Fusion Proteins
Benjamin, W. U., & Sun, Y. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23783 · Cited by 82
Aminomethylpyrimidines as novel DPP-IV inhibitors: A 105-fold activity increase by optimization of aromatic substituents
Peters, J., Weber, S., Kritter, S., Weiss, P., Wallier, A., Boehringer, M., Hennig, M., Kuhn, B., & Loeffler, B. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.01.019 · Cited by 83
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
Deacon, C. F. (2018) · Peptides · doi:10.1016/j.peptides.2017.10.011 · Cited by 85
Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: A case study
Li, M., Maderdrut, J. L., Lertora, J. J. L., & Batuman, V. (2007) · Peptides · doi:10.1016/j.peptides.2007.05.002 · Cited by 85
Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)
Hinke, S. A., Manhart, S., Pamir, N., Demuth, H.-U., Gelling, R. W., Pederson, R. A., & McIntosh, C. H. S. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00181-9 · Cited by 82
Self-citation
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 83
Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist
Li, Y., Zheng, X., Yi, X., Liu, C., Kong, D., Zhang, J., & Gong, M. (2017) · The FASEB Journal · doi:10.1096/fj.201601339r · Cited by 82
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes
Egan, J. M., Meneilly, G. S., & Elahi, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2002 · Cited by 83
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S. R. D., & Cherrington, A. D. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309020007 · Cited by 82
Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY
Unniappan, S., McIntosh, C. H. S., Demuth, H. U., Heiser, U. F., Wolf, R., & Kieffer, T. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0310-8 · Cited by 83
Self-citation
DPP4 Inhibitors: a new approach in diabetes treatment
Doupis, J., & Veves, A. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0076-1 · Cited by 83
Insulinotropic Hormone Glucagon-Like Peptide-1-(7-37) Appears Not to Augment Insulin-Mediated Glucose Uptake in Young Men during Euglycemia
Ryan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 81
Effect of ageing and diabetes on glucose‐dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose
Meneilly, G. S., Demuth, H. U., McIntosh, C. H. S., & Pederson, R. A. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00236.x · Cited by 81
Self-citation
Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling Pathways
Farkas, I., Vastagh, C., Farkas, E., Bálint, F., Skrapits, K., Hrabovszky, E., Fekete, C., & Liposits, Z. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00214 · Cited by 79
Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level
Alarcon, C., Wicksteed, B. L., & Rhodes, C. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0433-y · Cited by 82
Functional Maturation of Fetal Porcine β-Cells by Glucagon-Like Peptide 1 and Cholecystokinin
Hardikar, A. A., Wang, X. Y., Williams, L. J., Kwok, J. C., Wong, R., Yao, M., & Tuch, B. E. (2002) · Endocrinology · doi:10.1210/en.2001-211344 · Cited by 81
Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model
Li, Y., Liu, W., Li, L., & Hölscher, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.002 · Cited by 80
Dipeptidyl Peptidase IV Substrates
Meester, I. D., Lambeir, A., Proost, P., & Scharpé, S. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-306-47920-6_1 · Cited by 80
Intestinal feedback signaling and satiety
Moran, T. H., & Dailey, M. J. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.02.005 · Cited by 86
Porcine skin gelatin hydrolysate as a dipeptidyl peptidase IV inhibitor improves glycemic control in streptozotocin-induced diabetic rats
Huang, S.-L., Hung, C.-C., Jao, C., Tung, Y.-S., & Hsu, K. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.09.010 · Cited by 78
Gut Hormones and Energy Balance, The Future for Obesity Therapy?
Meiliana, A., & Wijaya, A. (2009) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v1i3.99 · Cited by 79
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes
Sutton, J. M., Clark, D. E., Dunsdon, S. J., Fenton, G., Fillmore, A., Harris, N. V., Higgs, C., Hurley, C. A., Krintel, S. L., MacKenzie, R. E., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.054 · Cited by 77
Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
Aso, Y., Ozeki, N., Terasawa, T., Naruse, R., Hara, K., Suetsugu, M., Takebayashi, K., Shibazaki, M., Haruki, K., Morita, K., et al. (2011) · Translational research · doi:10.1016/j.trsl.2011.09.005 · Cited by 77
Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones
Ionut, V., Hücking, K., Liberty, I. F., & Bergman, R. N. (2005) · Diabetologia · doi:10.1007/s00125-005-1709-3 · Cited by 77
Mass spectrometry for the quantification of bioactive peptides in biological fluids
Tamvakopoulos, C. (2006) · Mass Spectrometry Reviews · doi:10.1002/mas.20120 · Cited by 77
Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides
Kim, B.-J., Zhou, J., Martin, B., Carlson, O. D., Maudsley, S. R., Greig, N. H., Mattson, M. P., Ladenheim, E. E., Wustner, J., Turner, A., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166470 · Cited by 78
Incretins and other peptides in the treatment of diabetes
Todd, J. F., & Bloom, S. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02071.x · Cited by 76
Curcumin stimulates glucagon-like peptide-1 secretion in GLUTag cells via Ca2+/calmodulin-dependent kinase II activation
Takikawa, M., Kurimoto, Y., & Tsuda, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.092 · Cited by 78
The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics
Chae, S. Y., Choi, Y. G., Son, S., Jung, S. Y., Lee, D. S., & Lee, K. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.024 · Cited by 74
Chemoenzymatic Synthesis of Glycosylated Glucagon-like Peptide 1: Effect of Glycosylation on Proteolytic Resistance and in Vivo Blood Glucose-Lowering Activity
Ueda, T., Tomita, K., Notsu, Y., Ito, T., Fumoto, M., Takakura, T., Nagatome, H., Takimoto, A., Mihara, S.-I., Togame, H., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900261g · Cited by 74
The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion
Hjørne, A. P., Modvig, I. M., & Holst, J. J. (2022) · Metabolites · doi:10.3390/metabo12050420 · Cited by 79
Combination of the Dipeptidyl Peptidase IV Inhibitor LAF237 [(S)-1-[(3-Hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the Angiotensin II Type 1 Receptor Antagonist Valsartan [N-(1-Oxopentyl)-N-[[2′-(1 H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl]methyl]-l-valine] Enhances Pancreatic Islet Morphology and Function in a Mouse Model of Type 2 Diabetes
Cheng, Q., Law, P. K., de Gasparo, M., & Leung, P. S. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.142703 · Cited by 73
GLP1 and cancer: friend or foe?
Vangoitsenhoven, R., Mathieu, C., & der Schueren, B. V. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0111 · Cited by 77
Glucagon-like peptide-1 and glucagon-like peptide-2
Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 76

Authors: Kieffer, T. J., McIntosh, C. H., & Pederson, R. A.
Affiliations: University of British Columbia (CA)
ORCID: Kieffer, T J
Venue: Endocrinology
Publisher: The Endocrine Society
Published: 1995-08
Volume: 136
Issue: 8
Pages: 3585-3596
ISSN: 0013-7227 (ISSN-L)
1945-7170
DOI: 10.1210/endo.136.8.7628397
OpenAlex: W1978953702
Cited by: 1,124
References: 36
Citations by year: 2026: 9 · 2025: 31 · 2024: 30 · 2023: 15 · 2022: 27 · 2021: 36 · 2020: 23 · 2019: 37 · 2018: 25 · 2017: 40 · 2016: 39 · 2015: 54 · 2014: 47 · 2013: 53 · 2012: 61
FWCI: 6.60
Type: journal article
Language: en
Open access: closed
Locations: Endocrinology (publishedVersion)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
Novo Nordisk
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dipeptidyl peptidase IV, hormone degradation, incretin effect, N-terminal truncation, diprotin A, radiolabeled peptides, insulin secretion, circulating hormone levels
MeSH terms: Animals, Blood Physiological Phenomena, Glucagon-Like Peptides, Glucagon, Glucose, Peptide Fragments, Peptides, Protein Precursors, Rats, Inbred F344, Rats, Wistar, Dipeptidyl Peptidase 4, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks